Foralumab TZLS-401 100 µg

Phase 2

00%

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

2mo

TLSAPhase 2$153M

Foralumab TZLS-401 100 µg Phase 2 Results Expected

Foralumab TZLS-401 100 µg• Non-Active Secondary Progressive Multiple Sclerosis55

Apr 30Estimated

00%

Competitive Landscape

0 competitors in Non-Active Secondary Progressive Multiple Sclerosis

Drug Information

Target Indication

Non-Active Secondary Progressive Multiple Sclerosis

Clinical Trial

Last updated: 12/19/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

TLSA

Tiziana Life Sciences Ltd

Related Pipeline

Multiple System Atrophy

Secondary Progressive Multiple Sclerosis

Hepatocellular Carcinoma